Amgen Inc.'s legacy products saw significant declines in the first quarter in the face of generics and biosimilars, but the firm is confident newer products can eventually pick up the slack. However, sales of its new migraine therapy Aimovig (erenumab) declined from the fourth quarter.
[Sidebar#SC124569]








